We are literally chasing the coronavirus, the covid-19 virus like a hamster on a wheel. That is not just a saying, that is the truth of the matter when you look at rapidly emerging mutations of the covid-19 virus. While everyone is still focused on the delta strain, the lambda and the mu have already told Covid 1 to hold my beer. And of course, the propaganda machine wants to call it the pandemic of the unvaccinated while vaccinated people continue to catch the virus and in some cases die. But don’t get me wrong, this is not me making a case for or against vaccines. This is me making a case for a viable and feasible tool to help combat it. Ladies and gentlemen, Vaxart.

Subscribe: https://anchor.fm/moneytalksundayz/subscribe

Welcome to Money Talkz. If you’re new here, I’m your Investment Bro Stevie Bee. Leave a like, share, and or subscribe on your way in the door. If you’re feeling the episode and would like to see more, you can support the channel by clicking the link below. Let’s get into VXRT.

Vaxart Inc. (VXRT) is trending lower, roughly -4.57% in the recent trading with $8.19 being its most recent. The current price level is over -66.43% lower than the highest price of $24.90 over the past 52-weeks, but it is also 138.86% higher than the lowest price of $3.50 the company dropped to in the past 52-weeks. The latest news story on VXRT appeared in PR Newswire under the title “Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference”.

The conference was held over the last two days, and I’ll sum up what I’ve watched so far but before that, let’s talk charting.

VXRT in the last 30 days is trading almost 15% below its one month high and about 10% above its recorded lowest over the same time span. If you check the simple moving averages of VXRT, its 50-day-SMA is $8.27. It’s 5-day-SMA is 8.70. Vaxart’s 200-day-SMA is 7.55.

The stock’s 20-day average volume is at 4,041,925 shares and 50% of short-term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 7,578,720 shares. And to end, VXRT’s 100-day average volume is 15,462,688 shares with 100% of the long-term indicators pointing towards Buy for the stock.

In the bigger picture you can see it is trending higher overall.

Now it’s hard to say how well the stock will do in the long run. Investors like myself anxiously await the coveted pill that moves the needle as they say. I’m sure that the institutions holding VXRT shares are anxiously awaiting this pill as well since they own nearly 41%of the stock. The public owns 120.93 million shares and counting.

The latest SEC filings reveal that stock came across 7 new insider purchases involving 207,119 shares. On the other hand, VXRT has declared 272,958 shares sold in 9 insider transactions over the past three months.

How does Money Talkz feel about the stock? Just as bullish as ever. It’s a strong buy.

If you watched their presentation, you will see that their oral Covid vaccine candidate is backed by clinical data that the FDA found encouraging and promising enough to approve Vaxart to move on to Phase 2 clinical trials. That will being later this year. Considering that we’re already in mid-September and it hasn’t kicked off yet to our knowledge, I don’t expect the pill to be released by the end of the year. Maybe mid 2022 if we’re lucky.

While Covid is the hotly anticipated offering from VXRT however, the pipeline is focused on several oral tablets beyond the covid pill including norovirus, HPV, influenza & RSV.

But demand is super high for a Covid combatant and thus the focus is on their pill candidate. The pill promises a convenient mode of administration that is rapid and painless. No appointments, lines, or social distancing required.